Bogart Wealth LLC Grows Position in AbbVie Inc. $ABBV

Posted by Francis Steltz on Aug 21st, 2026

Bogart Wealth LLC raised its stake in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 6.4% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 45,098 shares of the company’s stock after purchasing an additional 2,706 shares during the quarter. Bogart Wealth LLC’s holdings in AbbVie were worth $11,348,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the stock. Vanguard Group Inc. raised its holdings in shares of AbbVie by 1.7% in the 4th quarter. Vanguard Group Inc. now owns 180,779,699 shares of the company’s stock worth $41,306,353,000 after purchasing an additional 3,032,438 shares during the period. State Street Corp lifted its stake in shares of AbbVie by 1.4% in the 4th quarter. State Street Corp now owns 80,940,931 shares of the company’s stock valued at $18,494,193,000 after purchasing an additional 1,119,274 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of AbbVie by 10.4% during the 4th quarter. Geode Capital Management LLC now owns 44,629,980 shares of the company’s stock worth $10,179,099,000 after purchasing an additional 4,190,487 shares during the period. Bank of America Corp DE increased its position in AbbVie by 1.4% during the 4th quarter. Bank of America Corp DE now owns 25,824,399 shares of the company’s stock worth $5,900,617,000 after purchasing an additional 356,394 shares in the last quarter. Finally, Norges Bank acquired a new stake in AbbVie during the 4th quarter worth approximately $5,865,055,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Price Performance

Shares of ABBV stock opened at $261.88 on Friday. AbbVie Inc. has a 12 month low of $190.75 and a 12 month high of $267.47. The firm has a market capitalization of $462.69 billion, a P/E ratio of 73.98, a P/E/G ratio of 0.88 and a beta of 0.30. The company’s fifty day moving average price is $247.72 and its two-hundred day moving average price is $227.22.

AbbVie (NYSE:ABBV – Get Free Report) last announced its earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating the consensus estimate of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The company had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. During the same period last year, the firm earned $2.97 earnings per share. The company’s revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, sell-side analysts anticipate that AbbVie Inc. will post 14.07 EPS for the current year.

AbbVie Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, August 14th. Investors of record on Wednesday, July 15th were issued a $1.73 dividend. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.6%. AbbVie’s dividend payout ratio is currently 195.48%.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

Positive Sentiment: AbbVie reached a new 52-week high. The move above its previous July peak signals continued buying interest and reinforces the stock’s strong uptrend. ABBV is trading well above its 50-day and 200-day moving averages. AbbVie Hits a New 52-Week High
Positive Sentiment: Analysts and dividend investors remain constructive on ABBV. AbbVie has gained about 19% in 2026, while its $1.73 quarterly dividend provides an annualized payout of $6.92 per share. Recent analyst views include buy ratings and price targets as high as $300, supporting the bullish case. Dividend Giants Pfizer, Chevron, AbbVie
Positive Sentiment: AbbVie completed a $10 billion senior-notes offering to help fund its Apogee Therapeutics acquisition. The financing supports expansion of AbbVie’s immunology and specialty-medicine pipeline, potentially helping offset future pressure from Humira competition. AbbVie Completes Senior Notes Offering
Neutral Sentiment: AbbVie paid €370 million in Irish corporation tax last year. The disclosure highlights the company’s significant Irish operations but is unlikely to materially change near-term earnings expectations. AbbVie Irish Corporation Tax
Negative Sentiment: Executive Vice President Nicholas Donoghoe sold 32,710 ABBV shares for approximately $8.18 million. The transaction reduced his direct holdings by about 30.5%. Although it may reflect personal financial planning, the sizable sale can weigh modestly on sentiment, particularly after the stock’s strong rally. AbbVie Insider Selling
Negative Sentiment: The Apogee acquisition financing increases AbbVie’s leverage. Investors will evaluate higher interest costs and whether Apogee’s pipeline can generate sufficient returns. ABBV also trades at a high earnings multiple, leaving less room for disappointing results.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. Guggenheim lifted their price target on shares of AbbVie from $261.00 to $288.00 and gave the company a “buy” rating in a research report on Tuesday, August 4th. Royal Bank Of Canada increased their price objective on shares of AbbVie from $260.00 to $280.00 and gave the stock an “outperform” rating in a research report on Friday, July 10th. UBS Group raised their target price on shares of AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a research note on Monday, July 13th. HSBC restated a “buy” rating and set a $300.00 target price on shares of AbbVie in a report on Monday, July 6th. Finally, BNP Paribas Exane increased their price target on AbbVie from $218.00 to $247.00 and gave the company a “neutral” rating in a report on Tuesday, August 11th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat, AbbVie currently has an average rating of “Moderate Buy” and an average price target of $275.95.

Check Out Our Latest Stock Report on AbbVie

Insiders Place Their Bets

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares in the company, valued at $18,607,500. The trade was a 30.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.06% of the stock is currently owned by company insiders.

About AbbVie

(Free Report)

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.